Project Grant R01AR085602
- Federal Project Grant Award Summary Funding Agency & Program: National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846) Award Details: Cleveland Clinic Lerner College of Medicine of Case Western Reserve University received $869,364 in federal funding awarded on August 22, 2025, with a project completion date of June 30, 2030. This Project Grant supports fundamental research to define...
- Federal Project Grant Award Summary The National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) awarded The Washington University a $378,228 Project Grant on September 10, 2025, under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846) to validate a novel preclinical rabbit model for hip pre-osteoarthritis (OA). The award, with completion scheduled for August 31, 2027, will deliver research products demonstrating the pathomechanical and...
- Federal Project Grant Award Summary Duke University's Office of Research Administration received a $540,974 Project Grant award from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846), effective September 19, 2025, through August 31, 2030. The award supports research to elucidate the role of Janus kinase (JAK) signaling in post-traumatic osteoarthritis (PTOA)-associated joint...
- Federal Grant Award Summary The National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) awarded New Jersey Institute of Technology a $330,107 Project Grant effective September 1, 2025, through June 30, 2030, under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846). This award supports fundamental research investigating the role of stress anisotropy—directional stress differences in extracellular matrices—in fibroblast activation and its...
- Federal Grant Award Summary The National Institute of Arthritis and Musculoskeletal and Skin Diseases awarded a $1.2M Project Grant to the University of Delaware (September 24, 2025–August 31, 2030) under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846) to develop and validate next-generation magnetic resonance imaging (MRI) methods for detecting bone fracture healing problems. The research addresses a significant clinical gap: the current lack of reliable...
- Federal Project Grant Award Summary Oklahoma State University received a $1.1 million Project Grant from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846), effective September 1, 2025 through July 31, 2028. The award funds development of gold nanocarrier technology designed to deliver methotrexate (MTX) directly to inflamed joints in rheumatoid arthritis (RA) patients who do...
- Federal Project Grant Award Summary The University of Missouri at Kansas City received a $570,174 Project Grant award dated September 15, 2025, from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846). This project, which extends through August 31, 2028, develops zonal-specific mineralized scaffolds designed to optimize osteochondral tissue regeneration by controlling collagen...
- Federal Grant Award Summary Rush University Medical Center received a $1.14 million Project Grant from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846), awarded September 5, 2025, with completion targeted for July 31, 2030. The grant funds development of comprehensive preclinical assessment tools and testing strategies to prevent fretting-corrosion in modular junctions of...
- Federal Grant Award Summary The National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) awarded the University of California, San Diego a $675,131 Project Grant effective August 1, 2025, through June 30, 2030, under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846). This award funds research to develop ultrashort echo time (UTE) magnetic resonance imaging (MRI) techniques for early detection of knee osteoarthritis (OA). The project addresses...
- Federal Grant Award Summary The University of Pennsylvania received a $1,258,558 Project Grant award dated September 5, 2025, from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846). The award funds development of dual-action nanoparticle-loaded microparticles for osteoarthritis treatment through June 30, 2030. The research addresses the clinical limitation of existing...
The University of Iowa received a $660,873 Project Grant from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846), awarded July 2, 2026, with completion targeted for April 30, 2031. The award supports research and development of carbon monoxide-gas entrapping materials (CO-GEMs) designed to prevent posttraumatic osteoarthritis (PTOA) through intraarticular injection. The project will advance these novel therapeutic materials toward clinical trials by characterizing their pharmacological effects, conducting preclinical safety assessments, and establishing a prospective clinical framework for treating joint degeneration following traumatic injury. The research deliverables include two primary aims: (1) determination of in vivo kinetics of intraarticular CO-GEM injections in rabbit models to establish that elevated carbon monoxide concentrations can be maintained in joints for at least one week, and (2) evaluation of in vivo effectiveness, safety mechanisms, and PTOA prevention capability through testing in two distinct relevant animal models. These rigorous preclinical studies are intended to generate critical safety and efficacy data necessary to support advancement of CO-GEMs into human clinical trials, addressing a significant unmet medical need in osteoarthritis treatment.Federal Project Grant Award Summary
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $660.9k | 7/6/26 |